Published in Pediatr Pulmonol on August 01, 1997
CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun (2000) 2.66
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy (2011) 2.06
Interaction of pseudomonas aeruginosa with epithelial cells: identification of differentially regulated genes by expression microarray analysis of human cDNAs. Proc Natl Acad Sci U S A (2000) 1.81
Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros (2011) 1.65
Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc (2007) 1.49
Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax (2001) 1.37
A549 lung epithelial cells grown as three-dimensional aggregates: alternative tissue culture model for Pseudomonas aeruginosa pathogenesis. Infect Immun (2005) 1.33
Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Am J Respir Crit Care Med (2006) 1.16
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clin Investig (Lond) (2015) 1.13
Recent advances in cystic fibrosis. Arch Dis Child (2001) 1.08
P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother (2001) 1.08
Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol (2011) 1.06
Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother (2007) 1.05
Induction of proinflammatory cytokines from human respiratory epithelial cells after stimulation by nontypeable Haemophilus influenzae. Infect Immun (2000) 1.05
Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax (2005) 1.04
Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol (2007) 1.02
Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol (2007) 1.02
Increase in exhaled carbon monoxide during exacerbations of cystic fibrosis. Thorax (2000) 0.98
"CF asthma": what is it and what do we do about it? Thorax (2002) 0.97
The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol (2009) 0.97
Influence of gender and interleukin-10 deficiency on the inflammatory response during lung infection with Pseudomonas aeruginosa in mice. Immunology (2002) 0.96
Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. Inflamm Res (2009) 0.96
Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress. Clin Biochem Rev (2009) 0.96
Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation. Open Respir Med J (2010) 0.96
Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax (2006) 0.94
Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax (2004) 0.93
Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia. Am J Respir Cell Mol Biol (2006) 0.93
Characterization of T cell clones derived from lymph nodes and lungs of Pseudomonas aeruginosa-susceptible and resistant mice following immunization with heat-killed bacteria. Clin Exp Immunol (2000) 0.91
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros (2014) 0.91
Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax (2006) 0.91
The protease-antiprotease battle in the cystic fibrosis lung. J R Soc Med (1999) 0.90
The effects of interleukin-8 on airway smooth muscle contraction in cystic fibrosis. Respir Res (2008) 0.89
Asthma in cystic fibrosis. J R Soc Med (2003) 0.88
The calpain, caspase 12, caspase 3 cascade leading to apoptosis is altered in F508del-CFTR expressing cells. PLoS One (2009) 0.88
Antibiotic and anti-inflammatory therapies for cystic fibrosis. Cold Spring Harb Perspect Med (2013) 0.84
Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. J Cyst Fibros (2008) 0.82
Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset. Expert Rev Mol Diagn (2011) 0.81
The role of inhaled corticosteroids in the management of cystic fibrosis. Paediatr Drugs (2009) 0.80
CFTR activity and mitochondrial function. Redox Biol (2013) 0.79
A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients. BMC Pediatr (2006) 0.79
Implication of NADPH oxidases in the early inflammation process generated by cystic fibrosis cells. ISRN Inflamm (2012) 0.76
Airway clearance devices for cystic fibrosis: an evidence-based analysis. Ont Health Technol Assess Ser (2009) 0.76
Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator. Respir Res (2006) 0.76
In vitro inhibition of neutrophil elastase activity by inhaled anti-Pseudomonas antibiotics used in cystic fibrosis patients. Mediators Inflamm (2010) 0.75
CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor. Expert Opin Orphan Drugs (2016) 0.75
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
Cortical language localization in left, dominant hemisphere. An electrical stimulation mapping investigation in 117 patients. J Neurosurg (1989) 4.18
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Attainment and adjustment in two geographical areas. I--The prevalence of psychiatric disorder. Br J Psychiatry (1975) 3.79
Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation (1990) 3.52
Hypoglycemic symptoms and frequency of severe hypoglycemia in patients treated with human and animal insulin preparations. Diabetes Care (1991) 3.51
Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol (1985) 3.50
Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med (1995) 3.47
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med (1994) 3.24
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem (2000) 2.71
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care (1987) 2.50
Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med (1999) 2.36
Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia (1983) 2.18
Sleep and depression--results from psychobiological studies: an overview. Biol Psychol (2001) 2.02
Effect of age on excess mortality in obesity. JAMA (1999) 2.01
Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia (1997) 1.95
Oxidative damage to DNA: formation, measurement, and biological significance. Rev Physiol Biochem Pharmacol (1997) 1.91
Glucose metabolism in perfused skeletal muscle. Effects of starvation, diabetes, fatty acids, acetoacetate, insulin and exercise on glucose uptake and disposition. Biochem J (1976) 1.90
The formation of glutamine and alanine in skeletal muscle. J Biol Chem (1974) 1.90
Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. The Bucharest-Düsseldorf Study. Diabetologia (1987) 1.87
Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Diabetologia (1990) 1.84
Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol (1995) 1.82
Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J (1974) 1.78
Glucose metabolism in perfused skeletal muscle. Interaction of insulin and exercise on glucose uptake. Biochem J (1975) 1.71
Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care (1985) 1.67
Effective and safe translation of intensified insulin therapy to general internal medicine departments. Diabetologia (1993) 1.67
Issues in the measurement of satisfaction with treatment. Am J Manag Care (1997) 1.67
Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest (1990) 1.66
Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-insoluble membrane domains. J Cell Biol (1998) 1.63
Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis (1995) 1.63
Assessment of excess mortality in obesity. Am J Epidemiol (1998) 1.62
Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci (1993) 1.61
Glucose metabolism in rat skeletal muscle at rest. Effect of starvation, diabetes, ketone bodies and free fatty acids. Diabetes (1974) 1.61
Health beliefs and compliance with inhaled corticosteroids by asthmatic patients in primary care practices. Respir Med (1999) 1.59
Lack of binding of human C3, in its native state, to C3b receptors. J Immunol (1981) 1.57
Evaluation of a structured treatment and teaching programme on non-insulin-dependent diabetes. Lancet (1988) 1.56
Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study. J Pediatr (1989) 1.53
The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol (1997) 1.52
Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect Immun (1983) 1.51
Prevalence of insomnia in elderly general practice attenders and the current treatment modalities. Acta Psychiatr Scand (1994) 1.51
Uncontrolled-rate freezing and storage at -80 degrees C, with only 3.5-percent DMSO in cryoprotective solution for 109 autologous peripheral blood progenitor cell transplantations. Transfusion (2001) 1.51
Noninvasive estimation of pulmonary artery diastolic pressure in patients with tricuspid regurgitation by Doppler echocardiography. Chest (1999) 1.51
Action profiles of fast onset insulin analogues. Diabetologia (1990) 1.50
Obstructive sleep apnea is a risk factor for difficult endotracheal intubation. Minerva Anestesiol (2011) 1.49
Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood (1997) 1.48
Unsuspected cardiac abnormalities in the acquired immune deficiency syndrome. An echocardiographic study. Chest (1989) 1.48
Echocardiographic detection of transient right heart thrombus: now you see it, now you don't. Am Heart J (1991) 1.48
Functional differences between the 40 kDa and 50 to 70 kDa IgG Fc receptors on human neutrophils revealed by elastase treatment and antireceptor antibodies. J Immunol (1988) 1.48
Test-retest reliability and validity of the Structured Interview for Sleep Disorders According to DSM-III-R. Am J Psychiatry (1993) 1.46
Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis (1988) 1.45
Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J Clin Invest (1988) 1.42
Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Diabetologia (1997) 1.42
Captopril, blood pressure, and diabetic nephropathy. JAMA (1994) 1.42
[Chronic fatigue syndrome. Definition, diagnostic measures and therapeutic possibilities]. Nervenarzt (1996) 1.42
Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci (1997) 1.41
Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med (1996) 1.41
Hemodialysis of children: a review. Tex Med (1976) 1.40
[Differential indications for psychotherapy exemplified by depression]. Nervenarzt (2011) 1.39
Diabetes care in cats and dogs. Diabet Med (2002) 1.39
[Significance of historical and current hallucinogenic research in psychiatry]. Nervenarzt (1993) 1.39
[The metabolic effects of beta-receptor blockers. What is of practical importance in antihypertensive therapy?]. Dtsch Med Wochenschr (1992) 1.39
Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med (1992) 1.38
HLA-DR2 and sleep onset REM periods in endogenous depression. Br J Psychiatry (1988) 1.38
Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol (1999) 1.38
Reliability of causes of death in persons with Type I diabetes. Diabetologia (2002) 1.38
Complement receptors. Clin Immunol Rev (1983) 1.37
[Addressed to the Federal Professional Society of Rehabilitation on "Planning ambulatory rehabilitation of psychosomatic and psychiatric diseases" 15 January 2003]. Nervenarzt (2003) 1.37
Radiation-induced decomposition of the purine bases within DNA and related model compounds. Int J Radiat Biol Relat Stud Phys Chem Med (1985) 1.36
Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol (2012) 1.36
Functional and molecular aspects of voltage-gated K+ channel beta subunits. Ann N Y Acad Sci (1999) 1.34
Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett (1991) 1.34
Exercise and diabetes mellitus. Diabetes (1979) 1.34
Exercise-induced fall of blood glucose in insulin-treated diabetics unrelated to alteration of insulin mobilization. Diabetes (1979) 1.33
Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. Infect Immun (1983) 1.31
Noncontact fluorescence diffuse optical tomography of heterogeneous media. Appl Opt (2007) 1.31
Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest (1992) 1.28
Studies on the mechanism of T cell inhibition by the Pseudomonas aeruginosa phenazine pigment pyocyanine. J Immunol (1987) 1.27
Mycobacterium tuberculosis 19-kDa lipoprotein promotes neutrophil activation. J Immunol (2001) 1.26
Cigarette-smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1 (insulin-dependent) diabetes. Diabetologia (1986) 1.26
A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4. J Immunol (1984) 1.26
The nephrotic syndrome secondary to acute glomerulonephritis during falciparum malaria. Ann Intern Med (1967) 1.25
Attainment and adjustment in two geographical areas: III--Some factors accounting for area differences. Br J Psychiatry (1975) 1.25
Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia (1994) 1.25
Systematic review and validation of prediction rules for identifying children with serious infections in emergency departments and urgent-access primary care. Health Technol Assess (2012) 1.25
Molecular cloning and characterization of murine and human N-acetylglucosamine kinase. Eur J Biochem (2000) 1.25
Patient education as the basis for diabetes care in clinical practice and research. Diabetologia (1985) 1.24
E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ (2009) 1.24
Prevalence of renal artery stenosis in diabetes mellitus--an autopsy study. J Intern Med (1991) 1.24
Attainment and adjustment in two geographical areas. II--The prevalence of specific reading retardation. Br J Psychiatry (1975) 1.24
Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes. Diabetes Care (1998) 1.23
Patient education - evaluation of a complex intervention. Diabetologia (2002) 1.23
Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med (1995) 1.23
Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia (1984) 1.23
Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med (1980) 1.23
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics. J Med Chem (2008) 1.22
Absorption kinetics of subcutaneously injected insulin. Evidence for degradation at the injection site. Diabetologia (1979) 1.22
Case-control study on stomach cancer in Germany. Int J Cancer (1991) 1.22